9th Annual Biomarkers Congress

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. New Signaling Mechanisms governing invasion and metastasis in vivo MD Anderson Cancer Center, Division of Cancer Medicine Grand Rounds November, 2009
2. 'Personalized Medicine and Cancer Care: What does the future hold? NA July, 2009
3. From Bench to Bedside and Beyond: Lessons Learned in the CTSA Network 2009 Delaware Health Sciences Alliance Research Conference May, 2009
4. Functional Significance of Nuclear Receptor Acetylation National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) Bethesda, MD, Chemical Approaches to Nuclear Receptors and Metabolism Symposium April, 2009
5. Breast Cancer Control 8th Annual Meeting March, 2009
6. New Signaling Mechanisms Governing Invasion and Metastasis in vivo NA February, 2009
7. Androgen receptor acetylation in hormone signaling. Thomas Jefferson University Prostate Cancer Seminar February, 2009
8. Acetylation of hormone-regulated nuclear receptors controls cellular growth H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Basic Research Grand Rounds February, 2009
9. Acetylation of hormone-regulated nuclear receptors controls cellular growth Lennox Black Symposium November, 2008
10. Cyclin D1 Regulates Micro RNA to Control Breast Cancer Cell Proliferation NA September, 2008
11. Epigenetic mechanisms involved in NR action 13th International Congress on Hormonal Steroids & Hormones and Cancer September, 2008
12. Death to the cultural cringe-Australians on the global stage NA September, 2008
13. New Signaling Mechanisms Governing Invasion and Metastasis in vivo NA September, 2008
14. Building an Intellectual Nation Queens College New York Reunion June, 2008
15. New Signaling Mechanisms Governing Invasion and Metastasis in vivo NA June, 2008
16. Stem Cells in Cancer Biology 1st Annual Jefferson Stem Cell Symposium June, 2008
17. New Gene Targets for Prostate Cancer Therapy and Aging Thomas Jefferson University, Philadelphia, PA, Prostate Cancer Symposium May, 2008
18. New Signaling Mechanisms Governing Invasion and Metastasis in vivo NA May, 2008
19. How does the world view us? Australia 2020 Summit April, 2008
20. New Signaling Mechanisms Governing Invasion and Metastasis in vivo NA April, 2008
21. New Signaling Mechanisms Governing Invasion and Metastasis in vivo. NA April, 2008
22. New Signaling Mechanisms Governing Invasion and Metastasis in Vivo Karmanos Cancer Institute, Detroit, MI, Grand Rounds March, 2008
23. New Signaling Mechanisms Governing Invasion and Metastasis in vivo Medical University of South Carolina, Hollings Cancer Center Grand Rounds February, 2008
24. New Signaling Mechanisms Governing Invasion and Metastasis In Vivo. Drexel University College of Medicine, Philadelphia, PA, Molecular and Cell Biology and Genetic Seminar Series November, 2007
25. New Signaling Mechanisms Governing invasion and metastasis in vivo 4th Tumor Progression & Therapeutic Resistance Conference October, 2007
26. Colon Cancer-Onset and Progression – New Molecular Targets Thomas Jefferson University, Philadelphia, PA, GI Grand Rounds September, 2007
27. Functional Significance of Acetylation of Androgen Nuclear Receptor Summer Conference on Mechanisms of Steroid Hormone Action July, 2007
28. Functional Significance of Nuclear Receptor Acetylation and Deacetylation – the Role of SIRTUINs The Gordon Research Conference on Hormone Action in Development and Cancer July, 2007
29. Acetylation and Deacetylation of Nuclear Receptors FASEB, Snowmass Village, CO, Summer Research Conferences, Histone Deacetylases (HDACs) in Health & Diseases, Seminar June, 2007
30. New signaling mechanisms governing invasion and metastasis in vivo NA June, 2007
31. Acetylation of Nuclear Receptors The Endocrine Society’s 89th Annual Meeting June, 2007
32. Cell Fate Determination Factors and the Cell Cycle in Breast Cancer Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Seminar May, 2007
33. Cell-cycle control in angiogenesis: the cell cycle goes inside-out Frontiers in Vascular Biology Seminar Series May, 2007
34. Acetylation of transcription factors regulates cellular growth University of Delaware, Newark, DE, Seminar April, 2007
35. Use of Breast Cancer Treatment Guidelines in Developing Countries 7th INCTR Annual Meeting March, 2007
36. Australians: Global Citizenship in Science NA January, 2007
37. The Hormonal Control of Nuclear Receptors and Cyclins in Hormone Signaling NA December, 2006
38. The Hormonal Control of Nuclear Receptors and Cyclins in Hormone Signaling University of Western Australia Dental School, Perth, Australia, Anniversary Research Symposium November, 2006
39. Light Activated Gene Therapy, New Selective Therapies for Disease Society of Nuclear Medicine, Key Biscayne, FL, Molecular Imaging: Shaping the Future July, 2006
40. Estrogens and Epigenetic Signals Estrogens and Human Disease Course May, 2006
41. Distinctions and Similarities: Three Perspectives 7th Annual Philadelphia-Japan Health Sciences Dialogue May, 2006
42. Understanding Basic Model of Cell-Cycle Control and Understanding the Basic Model of Androgen Regulated Gene Expression 12th Annual Anthony J. and Ruth H. Moretti Cancer Conference April, 2006
43. Nuclear Receptors & Cyclins in Hormone Signaling NA March, 2006
44. Nuclear Receptors and Cyclins in Hormone Signaling St. Jude’s Children’s Research Hospital, Memphis, TN, Danny Thomas Lecture Series March, 2006
45. Nuclear Receptors & Cyclins in Hormone Signaling National Institutes of Health, Bethesda, MD, Inter-Institute Endocrine Grand Rounds February, 2006
46. Cyclins and cdk’s: Targets for Cancer Therapy Signaling World 2006 Meeting January, 2006
47. Novel Functions of Cyclin D1: Regulation of Mitochondrial Metabolism Breast Cancer Symposium “Think Tank 16” Meeting January, 2006
48. New Approaches to the Treatment of Breast Cancer 6th INCTR Annual Meeting December, 2005
49. New Opportunities for Cancer Therapy. NA November, 2005
50. Nuclear Receptors and Cyclins in Hormone Signaling George Mason University, Manassas, VA, Research Seminar October, 2005
51. Approaches to 2-Hit Modeling in Mice NA May, 2005
52. Hormone and Cell Cycle Control: New Paradigms Wayne State University, Detroit, MI, Karmanos Cancer Center, Grand Rounds May, 2005
53. Novel Properties of Cyclin D1 in Cancer Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, Cancer Biology Program Seminar May, 2005
54. Lynne Cohen Foundation Symposium on the Emerging Role of Screening and Prevention in Women’s Cancer Boston University, Boston, MA, Evans Seminar Series May, 2005
55. Modeling of Microarray Data for Generating Transgenic Mice that Identify Molecular Genetic Pathways of Cancer Virginia Tech – National Capital Region, Riva San Vitale, Switzerland, Looking to the Future: Computational Methods in Drug Design April, 2005
56. Hormone and Cell Cycle Control: New Paradigms Lynne Cohen Foundation Symposium on the Emerging Role of Screening and Prevention in Women’s Cancer April, 2005
57. Novel properties of cyclin D1 in cancer University of Pennsylvania, Philadelphia, PA, Hematology-Oncology Grand Rounds November, 2004
58. Cell Cycle Control of Epigenetic Signals Regulating Aging and Cancer 4th Geneva Aging Workshop: Aging and Cancer at the Crossroads October, 2004
59. Cyclins and Cyclin Inhibitors in Hormonal Responsive Cancer NA October, 2004
60. Molecular Signatures of Cancer: Prognostication and Therapeutic Stratification Inova Fairfax Hospital, Fairfax, VA, Department of Medicine Grand Rounds September, 2004
61. The BRCA1 Tumor Suppressor in Signal Transduction and Oncogenesis. NA August, 2004
62. Cyclins and Cyclin Inhibitors in Hormonal Responsive Cancers Union Memorial Hospital, Baltimore, MD, Grand Rounds August, 2004
63. Epigenetics and cancer Masterfoods Inc, Mars, McLean, VA, Epigenetics: Fetal Origins of Health Multidisciplinary Research Unit Symposium June, 2004
64. Molecular Diagnostics and Cancer Care Washington Hospital Center, Washington, DC, Washington Cancer Institute Surgical Oncology Division Meeting May, 2004
65. Nuclear Receptors and Cyclins in Hormone Signaling NA April, 2004
66. Cyclin and Cyclin inhibitors in Hormonal Responsive Cancers. NA April, 2004
67. Nuclear Receptor and Cyclins in Hormone Signaling NA April, 2004
68. New Technologies and Care Parity: Building Allies in the Battle with Cancer Australian Embassy, Washington, DC, Young Australian Professionals Association Meeting April, 2004
69. Nuclear Receptors and Cyclins in Hormone Signaling NA February, 2004
70. Acetylation of Non Histone Substrates in Growth and Apoptosis Chromatin 2004 Meeting January, 2004
71. Novel properties of cyclin D1 in cancer. NA December, 2003
72. Control of Cell Cycle Progression in Breast Cancer. San Antonio Breast Cancer Symposium December, 2003
73. Enabling technologies: integration of tissue specific transgenics and microarray technologies SPORE in Breast Cancer November, 2003
74. Breast Cancer Research Diagnoses and Treatment: Old Fears, New Hopes Jewish Community Center, Rockville, MD, Jewish Women and Breast Cancer Conference: Breaking the Silence November, 2003
75. Revisiting retinoblastoma: Novel functions of cyclin D1 in tumorigenesis and fat cell differentiation NA October, 2003
76. Comprehensive Cancer Centers: Private-Public Partnerships International Life Science Summit October, 2003
77. Cyclin D1 in Gastrointestinal Cancers Insights into Gastrointestinal Physiology and Cancer, October, 2003
78. Novel Properties of Cyclin D1 in Cancer. NA September, 2003
79. Approaches to 2-hit modeling in mice NA August, 2003
80. Nuclear Receptors and Cyclins in Hormone Signaling. NA July, 2003
81. Nuclear Receptors and Cyclins in Hormone Signaling. NA May, 2003
82. Cyclins and cyclin inhibitors: novel targets for cancer therapy. NA April, 2003
83. Cyclin D1 and Mammary tumorigenesis Timing of Dietary Exposure and Breast Cancer Risk U54 Program Mini-Symposium: Prevention of Breast Cancer April, 2003
84. Nuclear Receptors and Cyclins in Hormone Signaling Frontiers of Estrogen Action Program April, 2003
85. Clinical Development of Oncologic Agents: Challenging the Tradition Georgetown University, Washington DC, Georgetown University Center for Drug Development Science Workshop April, 2003
86. Signal transduction based mouse models of Cancer. NA March, 2003
87. Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms. NIH Inter-Institute Endocrine Grand Rounds March, 2003
88. Novel Properties of Cyclin D1 in Cancer Breast Cancer Symposium “Think Tank 13” January, 2003
89. Cyclin D1 and nuclear receptors in apoptosis-novel pathways. Apoptosis 2003: From signaling pathways to therapeutic tools January, 2003
90. Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms 7th World Congress on Advances in Oncology and the 4th International Symposium on Molecular Medicine October, 2002
91. Cyclins and cyclin inhibitors in hormonal responsive tumors: new mechanisms University of Tokyo, Tokyo, Japan, Invited Lecture Series October, 2002
92. Nuclear receptor modifications and endocrine cell proliferation The International Congress on Hormonal Steroids and Hormones and Cancer October, 2002
93. Cyclins and cyclin inhibitors in hormonal-responsive tumors: novel mechanisms. 7th World Congress on Advances in Oncology and 5th International Symposium on Molecular Medicine October, 2002
94. Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms. NA September, 2002
95. Acetylation and Nuclear receptor function 3rd Geneva Aging Workshop September, 2002
96. Signaling pathways regulating cancer development” relevance of post-translational modifications NCI Workshop, Post-translational Modification: Implication for the Pathogenesis and Prevention of Cancer August, 2002
97. Nuclear receptor modifications and endocrine cell proliferation NA July, 2002
98. PPARg –mechanism of action in adipocyte differentiation Albert Einstein College of Medicine, NY, Diabetes Center meeting May, 2002
99. Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms. NA May, 2002
100. A key role for the breast oncogene cyclin D1 in fat differentiation and cellular migration NA March, 2002
101. What are the real breast cancer tumor suppressors and oncogenes knockout and transgenic mice provide new in vivo insights North Shore-LIJ Health System, Manhasset, NY, Combined Research Seminar Series December, 2001
102. Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms. NA December, 2001
103. The role of p27Kip1 as a mammary gland tumor suppressor using knockout and transgenic mice 6th World Congress on Advances in Oncology and the 4th International Symposium on Molecular Medicine October, 2001
104. Ponasterone regulated transgenics to study breast cancer in the mouse. The Jackson Laboratory, Bar Harbor, ME, Novel Mechanisms for Regulating Gene Expression in vivo conference August, 2001
105. Tissue specific inducible transgenics Albert Einstein College of Medicine, NY, NCI funded Mouse Developmental Genetics Course August, 2001
106. Cyclins and cyclin inhibitors in Hormonal responsive tumors: new mechanisms NA May, 2001
107. Histone acetylation and the cell-cycle in hormone signaling and cancer NA April, 2001
108. Acetylation and Nuclear receptor function 11th International Congress of Second Messengers and Phosphoproteins April, 2001
109. Cyclins and cyclin inhibitors in Hormonal responsive tumors: new mechanisms NA April, 2001
110. Cyclins and cyclin inhibitors in mammary tumorigenesis - new insights from knockout mice Albert Einstein College of Medicine, NY, Internal Faculty Seminar March, 2001
111. Cyclins and cyclin inhibitors in mammary tumorigenesis - new insights from knockout mice NA February, 2001
112. Cyclins and Cyclin inhibitors in hormonal responsive tumors: new mechanisms. Queen Elizabeth II Medical Center November, 2000
113. Cyclins and CDKs in breast cancer - new mouse models New York University, Department of Cell Biology Seminar series November, 2000
114. Nuclear receptor mutations in breast and prostate cancers 11th International Congress of Endocrinology November, 2000
115. The application of microarray analysis in the identification of Angiotensin II regulation of the Cell-cycle 11th International Congress of Endocrinology November, 2000
116. The role of cyclin D1 in the genesis of breast cancer Molecular and Genetic Basis of Breast Cancer Symposium October, 2000
117. The application of knockout and transgenic mice in breast cancer therapeutics 5th International Symposium on Biotechnology in Preventive Oncology October, 2000
118. New mechanisms governing hormone regulation of nuclear receptor signaling. Albert Einstein College of Medicine, NY, Diabetes Conference October, 2000
119. Cyclins and cyclin inhibitors in Hormonal responsive tumors: new mechanisms. University of Texas at San Antonio, TX, Department of Surgery seminar series August, 2000
120. Tissue specific inducible transgenics: A practical course in the construction of transgenic and knockout mice. Albert Einstein College of Medicine, NY, NCI funded Mouse Developmental Genetics Course August, 2000
121. Cyclins, CDKs and adrenal cellular proliferation Adrenal 2000, IXth International Conference on the Adrenal Cortex June, 2000
122. NF-kB and the cell-cycle.” International Conference on New Targets of the NF-kB Pathway for Novel Therapies in Cancer and Inflammation June, 2000
123. Cyclins and cyclin inhibitors in Hormonal responsive tumors: new mechanism NA May, 2000
124. Cyclins and cyclin inhibitors in mammary tumorigenesis - new insights from knockout mice NA April, 2000
125. Cyclins and cyclin inhibitors in cancer NA March, 2000
126. Cyclin D1 in bone and breast-Novel properties of cyclin D1 in cellular differentiation NA March, 2000
127. New insights into breast cancer from transgenic analysis of cell-cycle proteins. NA March, 2000
128. Cyclin D1, Cell-cycle dysregulation and cancer NA November, 1999
129. Cyclin D1 regulation by oncogenic and integrin linked signaling pathways. The Weizmann Institute of Science, Dead Sea, Israel, Advancement of Science in Israel, Bat-Sheva Seminar Meeting: The Dialogue between Cell Adhesion, Protein Degradation and Transcriptional Regulation in Cancer November, 1999
130. Cyclins and cyclin inhibitors in mammary tumorigenesis - new insights from knockout mice NA November, 1999
131. Novel functions of the D1 cyclin The State University of New York, Buffalo, University Research Seminar Series October, 1999
132. New insights into breast cancer from transgenic analysis of cell-cycle proteins NA September, 1999
133. New Tissue specific Inducible transgenics. NA September, 1999
134. Oncogene regulation of the cyclin D1 gene NA September, 1999
135. Tissue specific inducible transgenics, NCI funded Mouse Developmental Genetics Course NA August, 1999
136. Cyclin D1 in bone and breast-novel properties of cyclin D1 in cellular differentiation. NA July, 1999
137. New insights into breast cancer from transgenic analysis of cell-cycle proteins. NA July, 1999
138. Novel functions of the G1 cyclins NA June, 1999
139. Regulation of the p450 side chain cleavage gene; new transcriptional interactions in trans Albert Einstein College of Medicine, NY, Department of Medicine, Diabetes Research Seminar Series May, 1999
140. Oncogene regulation of the cyclin D1 gene in mammary epithelial cells. Georgetown UCHC Lombardi Comprehensive Cancer Center, DC February, 1999
141. Oncogene regulation of the cyclin D1 (PRAD1) gene in mammary epithelial cells University of Connecticut Health Science Center, Molecular Medicine Seminar February, 1999
142. The use of knockout mice to study human breast cancer Albert Einstein College of Medicine, NY, Department of Medicine Research Seminar Series February, 1999
143. Regulation of the p450 side chain cleavage gene - new transcriptional interactions in trans NA November, 1998
144. The molecular mechanisms of Erb-2 and pp60Src regulation of cyclin D1 and its kinase activity in mammary cells NA November, 1998
145. Oncogene regulation of the cyclin D1 gene NA October, 1998
146. The molecular mechanisms of Erb-2 and pp60Src regulation of cyclin D1 and its kinase activity in mammary cells NA October, 1998
147. Cyclin D1 and breast cancer - The role of Rho proteins and cyclin D1 in breast tumorigenesis and metastasis NA October, 1998
148. Cyclin D1 in mammary tumorigenesis. The use of Tissue specific inducible transgenics NA September, 1998
149. Cyclin D1 and breast cancer - new gene therapy approaches NA May, 1998
150. Regulation of cyclin D1 by breast oncogenes NA January, 1998
151. Inducible transgenics to study breast tumorigenesis NA January, 1998
152. Cyclin D1 in transgenic models of breast tumorigenesis NA December, 1997
153. The D-type cyclins-lynchpins in hormonal regulation of cellular proliferation and differentiation NA February, 1997
154. The D-type cyclins - lynchpins in hormonal regulation of cellular proliferation and differentiation NA January, 1997
155. Regulation of cyclin D1 NA January, 1997
156. Cyclin D1 in development and tumorigenesis. NA December, 1996
157. Cyclins in neural differentiation and breast tumorigenesis NA December, 1996
158. Cyclins in transgenic models of tumorigenesis NA November, 1996
159. Cyclin D1 in vascular smooth muscle cell proliferation and spontaneously hypertensive rat model NA November, 1996
160. pp60src regulation of cyclin D1 in breast tumorigenesis NA August, 1996
161. Oncogene regulation of cyclin D1 and transgenic models of breast tumorigenesis NA June, 1996
162. The role of cyclins in Angiotensin II induced cellular proliferation and in transgenic models of tumorigenesis NA May, 1996
163. Cyclin D1 regulation during development and in transgenic models of breast tumorigenesis M.D. Anderson Cancer Center April, 1996
164. Cyclins in transgenic models of tumorigenesis NA April, 1996
165. Cyclin D1 regulation during development and in transgenic models of breast tumorigenesis NA March, 1996



Site wide Speaking/Presenting-Abstract/Poster at Mtg

No events found.
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.